Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 6/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791593 | 0.87 | APP (0.56) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL12792438 | 0.85 | NPC1 (0.57) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL1658628 | 0.85 | APP (0.54) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL12082050 | 0.85 | SCN9A (0.56) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL12082137 | 0.85 | SCN9A (0.56) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL1656216 | 0.84 | APP (0.53) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL12082044 | 0.83 | SCN9A (0.57) | NPC1RAB9AAPPSCN9AKMT2A | |
| SCHEMBL1655886 | 0.82 | CTSV (0.57) | NPC1RAB9AHPGDALDH1A1KDM4E | |
| SCHEMBL1656425 | 0.82 | CTSV (0.57) | NPC1RAB9AHPGDALDH1A1KDM4E | |
| SCHEMBL1028006 | 0.81 | MEN1 (0.53) | NPC1RAB9AAPPSCN9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305633-B1 | Catechol derivative and its use | KISSEI PHARMACEUTICAL (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8258162-B2 | Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258162-B2 | Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258162-B2 | Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20110172208-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172208-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172208-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2305633-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE AND USE OF THE PHARMACEUTICAL COMPOSITION | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305633-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE AND USE OF THE PHARMACEUTICAL COMPOSITION | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172208-A1 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION | COMT, CYP3A5, CYP2D6 | NPC1 1305/4885RAB9A 1639/4885APP 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.